SERM gets FDA nod for breast cancer
Raloxifene (Evista, Lilly) is approved for breast cancer
Selective estrogen receptor modulator (SERM) raloxifene (Evista, Lilly) has been approved by the FDA for both reducing the risk of invasive breast cancer in postmenopausal women with osteoporosis and in women at high risk for invasive breast cancer. The drug works by blocking estrogen receptors in the breast. In clinical trials, raloxifene reduced the risk of invasive breast cancer by 44% to 71%. In a trial versus tamoxifen, both drugs showed similar risk of developing invasive breast cancer. More information can be accessed on-line at
Pharmacists Play Unique Role in Advancing Health Equity for Patients With Chronic Disease
December 7th 2023A new study, outlined in a poster at ASHP Midyear 2023, identified 3 key themes associated with the ways in which pharmacists are positioned to advance health equity for patients with chronic diseases.
